Skip to content

    Medical Reference Related to Prostate Cancer

    1. Prostate Cancer, Advanced or Metastatic - About This PDQ Summary

      Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about prostate cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus

    2. Prostate Cancer, Advanced or Metastatic - nci_ncicdr0000299612-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Genetics of Prostate Cancer

    3. Prostate Cancer, Advanced or Metastatic - About This PDQ Summary

      National Center for Complementary and Alternative Medicine (NCCAM) The National Center for Complementary and Alternative Medicine (NCCAM) at the National Institutes of Health (NIH) facilitates research and evaluation of complementary and alternative practices, and provides information about a variety of approaches to health professionals and the public.NCCAM ClearinghousePost Office Box 7923 Gaithersburg, MD 20898–7923Telephone: 1–888–644–6226 (toll free) 301–519–3153 (for International callers)TTY (for deaf and hard of hearing callers): 1–866–464–3615Fax: 1–866–464–3616E-mail: info@nccam.nih.gov Web site: http://nccam.nih.govCAM on PubMedNCCAM and the NIH National Library of Medicine (NLM) jointly developed CAM on PubMed, a free and easy-to-use search tool for finding CAM-related journal citations. As a subset of the NLM's PubMed bibliographic database, CAM on PubMed features more than 230,000 references and abstracts for CAM-related articles from

    4. Prostate Cancer, Advanced or Metastatic - nci_ncicdr0000258032-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer Screening

    5. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Complementary and alternative medicine - Patient Information [NCI] - Stage IV Prostate Cancer Treatment

      OverviewStage IV prostate cancer is defined by the American Joint Committee on Cancer's TNM classification system:[1]T4, N0, M0, any prostate-specific antigen (PSA), any Gleason.Any T, N1, M0, any PSA, any Gleason.Any T, any N, M1, any PSA, any Gleason.Extraprostatic extension with microscopic bladder neck invasion (T4) is included with T3a.Treatment selection depends on the following factors:Age.Coexisting medical illnesses.Symptoms.The presence of distant metastases (most often bone) or regional lymph node involvement only.The most common symptoms originate from the urinary tract or from bone metastases. Palliation of symptoms from the urinary tract with transurethral resection of the prostate (TURP) or radiation therapy and palliation of symptoms from bone metastases with radiation therapy or hormonal therapy are an important part of the management of these patients. Bisphosphonates may also be used for the management of bone

    6. Prostate Cancer, Advanced or Metastatic - nci_ncicdr0000719335-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer, Nutrition, and Dietary Supplements

    7. Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Get More Information From NCI

      Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support

    8. Prostate Cancer, Advanced or Metastatic - nci_ncicdr0000062853-nci-header

      This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at http://cancer.gov or call 1-800-4-CANCER.Prostate Cancer Prevention

    9. Prostate Cancer, Advanced or Metastatic - Changes to This Summary (08 / 22 / 2013)

      The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above. Editorial changes were made to this summary.

    10. Prostate Cancer, Advanced or Metastatic - Genes With Potential Clinical Relevance in Prostate Cancer Risk

      While genetic testing for prostate cancer is not yet standard clinical practice, research from selected cohorts has reported that prostate cancer risk is elevated in men with mutations in BRCA1, BRCA2, and on a smaller scale, in mismatch repair (MMR) genes. Since clinical genetic testing is available for these genes, information about risk of prostate cancer based on alterations in these genes is included in this section. In addition, mutations in HOXB13 were reported to account for a proportion of hereditary prostate cancer. Although clinical testing is not yet available for HOXB13 alterations, it is expected that this gene will have clinical relevance in the future and therefore it is also included in this section. The genetic alterations described in this section require further study and are not to be used

    Displaying 111 - 120 of 220 Articles << Prev Page 8 9 10 11 12 13 14 15 16 17 Next >>

    Today on WebMD

    man with doctor
    Symptoms, risks, treatments
    man coughing
    Men shouldn’t ignore
     
    prostate cancer cells
    What does this diagnosis mean?
    doctor and male patient
    Is it worth it?
     
    cancer fighting foods
    SLIDESHOW
    15 Cancer Symptoms Men Ignore
    FEATURE
     
    Prostate Enlarged
    VIDEO
    Picture Of The Prostate
    ANATOMY
     
    Prostate Cancer Quiz
    QUIZ
    screening tests for men
    SLIDESHOW
     
    Prostate Cancer Symptoms
    VIDEO
    Vitamin D
    SLIDESHOW